What did UBS do in the March 11, 2026 note on SGRY analyst rating?

UBS reiterated a **Buy** rating on Surgery Partners (SGRY) on March 11, 2026 and referenced an activist letter. The firm did not change its rating or issue a new price target in the public note.

Does the UBS action count as an SGRY upgrade or downgrade?

No. UBS's March 11, 2026 action was a maintenance of its **Buy** rating, so it is neither an upgrade nor a downgrade. It confirms prior positive coverage without new valuation guidance.

How did the market react to the SGRY analyst rating maintenance?

The stock moved about **1.2% ($0.16)** following the UBS reiteration, indicating a modest market reaction. Larger moves could follow if the activist pursues material governance or strategic changes.

What does the Meyka AI grade mean for SGRY analyst rating?

Meyka AI rates SGRY **B+**, reflecting relative strength versus the S&P 500, sector performance, growth metrics, and analyst consensus. This grade supplements analyst ratings but is not a recommendation.

Analyst Ratings

UBS Maintains Buy on Surgery Partners (SGRY) on March 11, 2026

ByDanny Kontos March 12, 2026

UBS maintained a Buy rating on Surgery Partners, Inc. (SGRY) on March 11, 2026. The SGRY analyst rating was reiterated after an activist letter to shareholders, according to StreetInsider coverage. UBS left the formal rating unchanged and did not publish a new price target with the note. The analyst action coincided with a modest stock move of 1.2% ($0.16) since the publication time. Investors should weigh the maintained Buy against recent activist pressure and broader sector dynamics.